Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AEX-2
Therapeutic Area : Sleep
Study Phase : Preclinical
Sponsor : NLS Pharmaceutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
NLS Pharmaceutics Secures Exclusive Global License for Dual Orexin Agonist Platform
Details : The agreement grants NLS global rights to next-gen oral OX1R/OX2R agonists, including AEX-2, tailored for narcolepsy, idiopathic hypersomnia, Parkinson's disease, dementia with Lewy bodies.
Brand Name : AEX-2
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
March 20, 2024
Lead Product(s) : AEX-2
Therapeutic Area : Sleep
Highest Development Status : Preclinical
Sponsor : NLS Pharmaceutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?